Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Cardiovascular Drugs and Therapy

• Publication date

  2018-03-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10557-018-6778-xPMID 29508169
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect and Regulation of the NLRP3 Inflammasome During Renal Fibrosis

  2020cited by this paper
• Blockade of the Adenosine A3 Receptor Attenuates Caspase 1 Activation in Renal Tubule Epithelial Cells and Decreases Interleukins IL-1β and IL-18 in Diabetic Rats

  2019cited by this paper
• High glucose stimulates cell proliferation and Collagen IV production in rat mesangial cells through inhibiting AMPK-KATP signaling

  2017cited by this paper
• SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor

  2017cited by this paper
• Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes.

  2017cited by this paper
• Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

  2017cited by this paper
• Interleukin-22 ameliorated renal injury and fibrosis in diabetic nephropathy through inhibition of NLRP3 inflammasome activation

  2017cited by this paper
• Liraglutide and Renal Outcomes in Type 2 Diabetes

  2017cited by this paper
• Dipeptidyl peptidase‑4 inhibitor sitagliptin prevents high glucose‑induced apoptosis via activation of AMP‑activated protein kinase in endothelial cells.

  2017cited by this paper
• Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice

  2017cited by this paper
• Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice

  2016cited by this paper
• Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome

  2016cited by this paper
• Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy/Ta mice, obese and type 2 diabetic animals

  2016cited by this paper
• Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

  2016cited by this paper
• Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

  2016cited by this paper
• β-Hydroxybutyrate suppresses inflammasome formation by ameliorating endoplasmic reticulum stress via AMPK activation

  2016cited by this paper
• The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels

  2016cited by this paper
• Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial

  2016cited by this paper
• Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation

  2016cited by this paper
• Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition.

  2015cited by this paper
• Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis

  2015cited by this paper
• Inhibition of Kidney Proximal Tubular Glucose Reabsorption Does Not Prevent against Diabetic Nephropathy in Type 1 Diabetic eNOS Knockout Mice

  2014cited by this paper
• The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.

  2014cited by this paper
• Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.

  2014cited by this paper
• Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice

  2014cited by this paper
• SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.

  2014cited by this paper
• Effects of sodium‐glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin‐induced type 1 diabetic rats

  2014cited by this paper
• Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.

  2013cited by this paper
• NOD-like and Toll-like receptors or inflammasomes contribute to kidney disease in a canonical and a non-canonical manner.

  2013cited by this paper
• Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus.

  2013cited by this paper
• Effects of a New SGLT2 Inhibitor, Luseogliflozin, on Diabetic Nephropathy in T2DN Rats

  2013cited by this paper
• Allopurinol, quercetin and rutin ameliorate renal NLRP3 inflammasome activation and lipid accumulation in fructose-fed rats.

  2012cited by this paper
• Nlrp3 Inflammasome Activation in Type 2 Diabetes: Is It Clinically Relevant?

  2012cited by this paper
• Upregulated NLRP3 Inflammasome Activation in Patients With Type 2 Diabetes

  2012cited by this paper
• The inflammasomes in kidney disease.

  2011cited by this paper
• NLRP3 inflammasomes link inflammation and metabolic disease.

  2011cited by this paper
• BTBR Ob/Ob mutant mice model progressive diabetic nephropathy.

  2010cited by this paper
• Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes

  2010cited by this paper
• A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy.

  2007cited by this paper

• [Immunometabolic disorders in type 2 diabetes mellitus mediated by NLRP3 inflammasome activation and methods of pharmacological correction thereof].

  2026cites this paper
• Imeglimin-based therapies improve glycemic control and reduce mitochondrial stress in type 2 diabetes: a prospective cohort study

  2025cites this paper
• SGLT2 inhibition attenuates diabetic tubulopathy by suppressing SGK1-mediated pyroptosis

  2025cites this paper
• Dapagliflozin attenuates diabetic cardiomyopathy via NRF2 protein upregulation-driven glutathione synthesis to inhibit myocardial ferroptosis.

  2025cites this paper
• Dapagliflozin ameliorates metabolic and hepatic outcomes in a mouse model of metabolic dysfunction-associated steatotic liver disease and diabetes

  2025cites this paper
• Jiedutongluotiaogan Formula Improves Pancreatic Dysfunction in db/db Mice through Modulating the Gut Microbiota-short Chain Fatty Acids-NLR Family, Pyrin Domain–containing Protein 3 Inflammasome

  2025cites this paper
• Acacetin Prevents Renal Damage Induced by Streptozotocin via Altering the NF‐κB/ASC/NLRP3 and AMPK/SIRT1 Pathways in Mice

  2025cites this paper
• Use of Sodium‐Glucose Transport Protein 2 Inhibitors and the Incidence of Urolithiasis: A Multi‐Database and Cross‐Country Study in Patients With Type 2 Diabetes Mellitus

  2025cites this paper
• The BTBR T+ Itpr3tf/J mouse strain as a model to study the genetic, immune, and metabolic origins of neurodevelopmental disorders

  2025cites this paper
• Sodium-Glucose Transporter-2 Inhibitors (SGLT2i) and Myocardial Ischemia: Another Compelling Reason to Consider These Agents Regardless of Diabetes

  2025cites this paper
• Targeting senescence to prevent diabetic kidney disease: Exploring molecular mechanisms and potential therapeutic targets for disease management

  2024cites this paper
• The Role of Mitochondria in Diabetic Kidney Disease and Potential Therapeutic Targets

  2024cites this paper
• Impact of DPP-4 Inhibitors on Interleukin Levels in Type 2 Diabetes Mellitus

  2024cites this paper
• Inibidores de SGLT2 e inflamassoma NLRP3: alvo potencial na doença renal do diabetes

  2024cites this paper
• SGLT2 inhibitors and NLRP3 inflammasome: potential target in diabetic kidney disease

  2024cites this paper
• Uncovering the Role of Anoikis-Related Genes in Modulating Immune Infiltration and Pathogenesis of Diabetic Kidney Disease

  2024cites this paper
• Effect of dipeptidyl peptidase-4 inhibitors on tumor necrosis factor alpha levels in patients with type 2 diabetes mellitus

  2024cites this paper
• Dapagliflozin dampens liver fibrosis induced by common bile duct ligation in rats associated with the augmentation of the hepatic Sirt1/AMPK/PGC1α/FoxO1 axis.

  2024cites this paper
• Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus

  2024cites this paper
• Association of novel antihyperglycemic drugs versus metformin with decrease in asthma exacerbations.

  2024cites this paper
• Dapagliflozin prevents kidney podocytes pyroptosis via miR-155-5p/HO-1/NLRP3 axis modulation.

  2024cites this paper
• Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors.

  2024cites this paper
• Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress.

  2024cites this paper
• Dapagliflozin ameliorates diabetic renal injury through suppressing the self-perpetuating cycle of inflammation mediated by HMGB1 feedback signaling in the kidney.

  2023cites this paper
• Sodium–Glucose Transporter 2 (SGLT2) Inhibitors and Iron Deficiency in Heart Failure and Chronic Kidney Disease: A Literature Review

  2023cites this paper
• Salvianolic acid B attenuates diabetic nephropathy through alleviating ADORA2B, NALP3 inflammasome, and NFκB activity.

  2023cites this paper
• On the wake of metformin: do anti-diabetic SGLT2 inhibitors exert anti-aging effects?

  2023cites this paper
• Dapagliflozin in patients with critical illness: rationale and design of the DEFENDER study

  2023cites this paper
• Integrative bioinformatics analysis of biomarkers and pathways for exploring the mechanisms and molecular targets associated with pyroptosis in type 2 diabetes mellitus

  2023cites this paper
• SGLT-2i: Nanoparticular-Based Strategies, Solutions, and Clinical Applications in Opposition to Low Bioavailability

  2023cites this paper
• Immunological Approaches in the Treatment of Diabetic Nephropathy.

  2023cites this paper
• Dapagliflozin ameliorated retinal vascular permeability in diabetic retinopathy rats by suppressing inflammatory factors.

  2023cites this paper
• Role of NLRP3 inflammasome in diabetes and COVID-19 role of NLRP3 inflammasome in the pathogenesis and treatment of COVID-19 and diabetes NLRP3 inflammasome in diabetes and COVID-19 intervention

  2023cites this paper
• Bibliometric and visual analysis of diabetes and pyroptosis from 2011 to 2022

  2023cites this paper
• ANIMAL MODELS OF DIABETIC NEPHROPATHY

  2023cites this paper
• Slowing the Progression of Diabetic Kidney Disease

  2023cites this paper
• The activation of spliced X-box binding protein 1 by isorhynchophylline therapy improves diabetic encephalopathy

  2023cites this paper
• A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy.

  2023cites this paper
• Bibliometric and visual analysis of diabetes mellitus and pyroptosis from 2011 to 2022

  2023cites this paper
• Lactobacillus Plantarum NC8 and its metabolite acetate alleviate type 1 diabetes via inhibiting NLRP3.

  2023cites this paper
• Empagliflozin improves renal ischemia–reperfusion injury by reducing inflammation and enhancing mitochondrial fusion through AMPK–OPA1 pathway promotion

  2023cites this paper
• SGLT-2 Inhibitors and the Inflammasome: What’s Next in the 21st Century?

  2023cites this paper
• BACE cleavage of APP does not drive the diabetic phenotype of PLB4 mice.

  2023cites this paper
• The Pathophysiological Basis of Diabetic Kidney Protection by Inhibition of SGLT2 and SGLT1.

  2022cites this paper
• Inflammation as A Precursor of Atherothrombosis, Diabetes and Early Vascular Aging

  2022cites this paper
• Fucoidan Alleviates Renal Fibrosis in Diabetic Kidney Disease via Inhibition of NLRP3 Inflammasome-Mediated Podocyte Pyroptosis

  2022cites this paper
• An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors

  2022cites this paper
• Neuroprotective effect of liraglutide in an experimental mouse model of multiple sclerosis: role of AMPK/SIRT1 signaling and NLRP3 inflammasome

  2022cites this paper
• Fructose Induces Insulin Resistance of Gestational Diabetes Mellitus in Mice via the NLRP3 Inflammasome Pathway

  2022influential citation
• Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models

  2022cites this paper
• Impact of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Aging—What Do We Know So Far? (A Narrative Review)

  2022cites this paper
• Metabolic Dysfunction in the Regulation of the NLRP3 Inflammasome Activation: A Potential Target for Diabetic Nephropathy

  2022cites this paper
• Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes

  2022cites this paper
• Sodium-glucose Cotransporter Type 2 Inhibitors: A New Insight into the Molecular Mechanisms of Diabetic Nephropathy.

  2022cites this paper
• A Glimpse of Inflammation and Anti-Inflammation Therapy in Diabetic Kidney Disease

  2022cites this paper
• Research Progress on the Role of Cell Pyroptosis in the Occurrence and Development of Diabetic Nephropathy

  2022cites this paper
• Cardiovascular protection by SGLT2 inhibitors – Do anti-inflammatory mechanisms play a role?

  2022cites this paper
• Advances in the Pathogenesis of Pyroptosis in Diabetic Nephropathy

  2022cites this paper
• MD Simulation Studies for Selective Phytochemicals as Potential Inhibitors against Major Biological Targets of Diabetic Nephropathy

  2022cites this paper
• Canagliflozin interrupts mTOR-mediated inflammatory signaling and attenuates DMBA-induced mammary cell carcinoma in rats.

  2022cites this paper
• Therapeutic efficacy of dapagliflozin on diabetic kidney disease in rats.

  2022cites this paper
• Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis

  2022cites this paper
• Empagliflozin suppresses urinary mitochondrial DNA copy numbers and interleukin-1β in type 2 diabetes patients

  2022cites this paper
• Mitochondrial Contribution to Inflammation in Diabetic Kidney Disease

  2022cites this paper
• Effects and mechanisms of SGLT2 inhibitors on the NLRP3 inflammasome, with a focus on atherosclerosis

  2022cites this paper
• Crocin alleviates the inflammation and oxidative stress responses associated with diabetic nephropathy in rats via NLRP3 inflammasomes.

  2021cites this paper
• Renoprotective mechanisms of SGLT2 inhibitor in diabetic kidney disease

  2021cites this paper
• GSDMD-mediated pyroptosis: a critical mechanism of diabetic nephropathy

  2021cites this paper
• Pyroptosis: A possible link between obesity‐related inflammation and inflammatory diseases

  2021cites this paper
• Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists

  2021cites this paper
• Promise of the NLRP3 Inflammasome Inhibitors in In Vivo Disease Models

  2021cites this paper
• SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes

  2021cites this paper
• Potential Therapeutic Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in the Context of Ischemic Heart Failure: A State-Of-The-Art Review.

  2021cites this paper
• Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations

  2021cites this paper
• Bruton's tyrosine kinase regulates macrophage-induced inflammation in the diabetic kidney via NLRP3 inflammasome activation

  2021cites this paper
• Ticagrelor and Dapagliflozin Have Additive Effects in Ameliorating Diabetic Nephropathy in Mice with Type-2 Diabetes Mellitus

  2021cites this paper
• Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways

  2021cites this paper
• Dioscorea zingiberensis ameliorates diabetic nephropathy by inhibiting NLRP3 inflammasome and curbing the expression of p66Shc in high-fat diet/streptozotocin-induced diabetic mice.

  2021cites this paper
• SGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical Benefits

  2021cites this paper
• New Insights into the Mechanisms of Pyroptosis and Implications for Diabetic Kidney Disease

  2020influential citation
• Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib

  2020cites this paper
• A minireview: Role of AMP-activated protein kinase (AMPK) signaling in obesity-related kidney injury.

  2020cites this paper
• Scutellarin protects against lipopolysaccharide-induced behavioral deficits by inhibiting neuroinflammation and microglia activation in rats.

  2020cites this paper
• Targeting NLRP3 inflammasome as a promising approach for treatment of diabetic nephropathy: Preclinical evidences with therapeutic approaches.

  2020cites this paper
• Acupuncture Reduces Hypertrophy and Cardiac Fibrosis, and Improves Heart Function in Mice with Diabetic Cardiomyopathy

  2020cites this paper
• The Inflammasome in Chronic Complications of Diabetes and Related Metabolic Disorders

  2020cites this paper
• The NLRP3 inflammasome as a bridge between neuro-inflammation in metabolic and neurodegenerative diseases.

  2020cites this paper
• Dihydrolipoic acid protects against lipopolysaccharide-induced behavioral deficits and neuroinflammation via regulation of Nrf2/HO-1/NLRP3 signaling in rat

  2020cites this paper
• Rodent models of diabetic kidney disease: human translatability and preclinical validity.

  2020cites this paper
• Diabetes and Calcification: The Potential Role of Anti-Diabetic Drugs on Vascular Calcification Regression.

  2020cites this paper
• SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in db/db Mice, a Model of Type 2 Diabetes

  2020cites this paper
• Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review.

  2020cites this paper
• Effect of Insulin on Proximal Tubules Handling of Glucose: A Systematic Review

  2020cites this paper
• Effect and Regulation of the NLRP3 Inflammasome During Renal Fibrosis

  2020cites this paper
• Opportunities for future therapeutic interventions for hyperoxaluria: targeting oxidative stress

  2019influential citation
• Central role of obesity in endothelial cell dysfunction and cardiovascular risk.

  2019cites this paper
• Mirtazapine suppresses sterile inflammation through NLRP3-inflammasome in diabetic rat kidney.

  2019cites this paper
• DPP-4 Inhibition Leads to Decreased Pancreatic Inflammatory Profile and Increased Frequency of Regulatory T Cells in Experimental Type 1 Diabetes

  2019cites this paper
• A new research hot spot: The role of NLRP3 inflammasome activation, a key step in pyroptosis, in diabetes and diabetic complications.

  2019cites this paper
• Do Drugs That Ameliorate Epicardial Adipose Tissue Inflammation Have Concordant Benefits on Atrial Fibrillation and on Heart Failure with a Preserved Ejection Fraction?

  2019cites this paper